Genentech’s KRAS G12C inhibitor divarasib shines in NSCLC phase III

AI Briefing

• – • Genentech's divarasib shows significant efficacy in NSCLC patients with KRAS G12C mutations in phase III trials.
• – • Divarasib demonstrated improved progression-free survival and overall survival compared to chemotherapy in NSCLC patients.
• – • Results indicate divarasib is a promising treatment option for patients with KRAS G12C mutations in NSCLC.